David H. Fater, CEO of Vicor Technologies, Inc. announced that on October 12, 2010 the US Patent Office issued United States Patent #7,811,992 to Vicor for the use of a molecule discovered using the company's novel drug discovery platform. The molecule covered by the patent has been shown to diminish the size and severity of infarctions associated with acute myocardial infarctions (heart attacks) and strokes.

"The molecule for which this patent was issued addresses two major therapeutic areas – heart attacks and strokes – that represent a vast market opportunity for Vicor. Receipt of this patent is an important milestone for Vicor as this is the first United States patent awarded to Vicor for its drug discovery platform," stated Fater

Vicor has filed several patent applications associated with its state-dependent drug discovery platform, which identifies peptides and proteins derived from variations in physiologies of an animal during hibernation (as compared with an animal not in hibernation). This platform may be used to advance the treatment of an array of human disease states, including stroke (cerebral ischemia), heart attack (cardiac ischemia), kidney failure, hypertension, obesity, cancer, and organ transplant/preservation. It also has the potential to reduce the cost, time, and risk associated with bringing related pharmaceuticals to market. Vicor has received 12 international patents related to this platform; countries from which Vicor has received patents include Armenia, Australia, Russia, and South Africa. In 2003, to conserve cash and focus on obtaining 510(k) marketing clearance from the U.S. Food and Drug Administration for diagnostics using its patented, proprietary PD2i nonlinear algorithm, Vicor suspended research related to its drug discovery platform. Research related to Vicor's drug discovery platform remains in the pre-clinical testing phase as the company awaits additional patent issuances and sufficient funding to continue research related to its drug discovery platform.

"While the studies that have prompted filing for patents associated with our drug discovery platform have only been performed in animals on a pre-clinical basis, this is very positive news. This patent provides us with protection for our advancements in the treatment of acute myocardial infarctions and strokes. With this protection, we can evaluate the most appropriate strategy to generate shareholder value for this platform," stated  Fater.

Vicor Technologies is a biotechnology company creating innovative non-invasive diagnostics employing its patented, proprietary point correlation dimension algorithm (PD2i). The PD2i nonlinear algorithm is a deterministic, nonlinear measure of electrophysiological potentials that predicts future pathological events with a high degree of accuracy in target populations.